Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Evaluating the Clinical Relevance of Thrombin Generation Potential during Emicizumab Therapy

Konrad Van Der Zwet, Mark Roest, Dana Huskens, Eduard J. Van Beers, Kathelijn Fischer, Lize Fie Ditteke Van Vulpen, Roger EG Schutgens, Rolf T. Urbanus

Blood (2024) 144 (Supplement 1): 3960.

https://doi.org/10.1182/blood-2024-204587

Published: 2024

Journal Articles

A Short Thrombin Generation Time-to-Peak/Lag Time Ratio Is an Independent Risk Factor for Mortality in the General Population

Romy De Laat-Kremers, Simona Costanzo, Mark Roest, Amalia de Curtis, Dana Huskens, Augusto Di Castelnuovo, Marisa Ninivaggi, Chiara Cerletti, Maria Benedetta Donati, Bas De Laat, Licia Iacoviello

Blood (2023) 142 (Supplement 1): 3989.

https://doi.org/10.1182/blood-2023-189881

Published: 2023

Journal Articles

Hemostasis Biomarkers and Long-Term Risk of Recurrent Cardiovascular Events and Bleeding Complications in Young Patients with an Ischemic Stroke

Janneke Spiegelenberg, Mark Roest, Bas De Laat, Marleen van Gelder, Saskia Middeldorp, Anil Tuladhar, Jenneke Leentjens, Frank-Erik De Leeuw

Blood (2023) 142 (Supplement 1): 2645.

https://doi.org/10.1182/blood-2023-187152

Published: 2023

Journal Articles

Cellular Components in Whole Blood Contribute to the Development of Thromboembolic Events in Patients with Pancreatic Cancer

Ruth A.L. Willems, Mark Roest, Judith de Vos-Geelen, Bas de Laat, Hugo Ten Cate

Blood (2023) 142 (Supplement 1): 1286.

https://doi.org/10.1182/blood-2023-185655

Published: 2023

Journal Articles

Diversity of Plasmatic Thrombin Pools Regulate Thrombin Generation and Blood Clotting: Interference By a Novel Nanobody

Siyu Sun, Joke Konings, Rolf T. Urbanus, Dana Huskens, Frauke Swieringa, Romy De Laat-Kremers, Jinmi Zou, Philip G. De Groot, Mark Roest, Johan W. M. Heemskerk, Bas De Laat

Blood (2023) 142 (Supplement 1): 3978.

https://doi.org/10.1182/blood-2023-185665

Published: 2023

Journal Articles

The Variable Heavy Chain Antibody Syn-VWFA1 Inhibits the Interaction of Platelets to Von Willebrand Factor in Solution but Not to Immobilized Von Willebrand Factor Thereby Inhibiting 3-Dimensional but Not 2-Dimensional Thrombus Formation

Dana Huskens, Lisa Nynke Van Der Vorm, Joke Konings, Nicholas Arce, Mark Roest, Philip G. De Groot, Renhao Li, Jasper A. Remijn, Bas De Laat

Blood (2023) 142 (Supplement 1): 1193.

https://doi.org/10.1182/blood-2023-177887

Published: 2023

Journal Articles

Domain Specificity of Anti-Prothrombin Antibodies That Express Lupus Anticoagulant Activity

Rachel Gehlen, Tessa Noordermeer, Arne Vandevelde, Walid Chayoua, Marisa Ninivaggi, Romy De Laat-Kremers, Mark Roest, Philip G. De Groot, Katrien M.J. Devreese, Rolf T. Urbanus, Bas De Laat

Blood (2023) 142 (Supplement 1): 5529.

https://doi.org/10.1182/blood-2023-185610

Published: 2023

Journal Articles

A Novel Plasminogen Activator Anti-Fibrin-uPA Increases the Sensitivity of the Plasmin Generation Assay to Therapeutic Target PAI-1

Ilaria De Simone, Mark Roest, Alisa S Wolberg, Bas de Laat, Dana Huskens

Blood (2023) 142 (Supplement 1): 5464.

https://doi.org/10.1182/blood-2023-181509

Published: 2023

Journal Articles

Flow Cytometric Analysis of Platelet Function in Patients on Antiplatelet Therapy and Suspected Thrombocytopathy

Dana Huskens, PhD, Mark Roest, PhD, Lisa Florin, Bas De Laat, MD, PhD, Katrien Devreese, PhD MD

Blood (2018) 132 (Supplement 1): 1161.

https://doi.org/10.1182/blood-2018-99-110295

Published: 2018

Journal Articles

Characterization of a Nanobody That Binds Von Willebrand Factor and Prevents Von Willebrand Factor Cleavage By Plasmin

Lisa N. Van Der Vorm, Adam Miszta, PhD, Alicia Veninga, M.Sc., Mark Roest, PhD, Jasper A. Remijn, PhD, Dana Huskens, PhD, Bas De Laat, MD PhD

Blood (2017) 130 (Supplement 1): 1031.

https://doi.org/10.1182/blood.V130.Suppl_1.1031.1031

Published: 2017

Journal Articles

No Association Between Platelet Function and Hemophilia B Phenotype

Roger E.G. Schutgens, MD PhD, Esther R. van Bladel, MD PhD, Kathelijn Fischer, MD PhD MSC, Mark Roest, PhD, Rolf Urbanus, PhD

Blood (2014) 124 (21): 4994.

https://doi.org/10.1182/blood.V124.21.4994.4994

Published: 2014

Journal Articles

Active von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome

Agon Hyseni, Hans Kemperman, Dylan W. de Lange, Jozef Kesecioglu, Philip G. de Groot, Mark Roest

Blood (2014) 123 (14): 2153–2156.

https://doi.org/10.1182/blood-2013-08-508093

Published: 2014

Journal Articles

Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts

Esther R. van Bladel, Annemieke G. Laarhoven, Laila B. van der Heijden, Katja M. Heitink-Pollé, Leendert Porcelijn, C. Ellen van der Schoot, Masja de Haas, Mark Roest, Gestur Vidarsson, Philip G. de Groot, Marrie C. A. Bruin

Blood (2014) 123 (10): 1556–1563.

https://doi.org/10.1182/blood-2013-08-519686

Published: 2014

Includes: Supplemental data

Journal Articles

β 2 -glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome

H. Bas de Laat, Ronald H.W.M. Derksen, Rolf T. Urbanus, Mark Roest, Philip G. de Groot

Blood (2004) 104 (12): 3598–3602.

https://doi.org/10.1182/blood-2004-03-1107

Published: 2004

Journal Articles

Platelet adhesion to collagen in healthy volunteers is influenced by variation of both α 2 β 1 density and von Willebrand factor

Mark Roest, Jan J. Sixma, Ya-Ping Wu, Martin J. W. Ijsseldijk, Mariëlle Tempelman, Pieter J. Slootweg, Philip G. de Groot, G. Henrita van Zanten

Blood (2000) 96 (4): 1433–1437.

https://doi.org/10.1182/blood.V96.4.1433

Published: 2000

NARROW

Evaluating the Clinical Relevance of Thrombin Generation Potential during Emicizumab Therapy

A Short Thrombin Generation Time-to-Peak/Lag Time Ratio Is an Independent Risk Factor for Mortality in the General Population

Hemostasis Biomarkers and Long-Term Risk of Recurrent Cardiovascular Events and Bleeding Complications in Young Patients with an Ischemic Stroke

Cellular Components in Whole Blood Contribute to the Development of Thromboembolic Events in Patients with Pancreatic Cancer

Diversity of Plasmatic Thrombin Pools Regulate Thrombin Generation and Blood Clotting: Interference By a Novel Nanobody

The Variable Heavy Chain Antibody Syn-VWFA1 Inhibits the Interaction of Platelets to Von Willebrand Factor in Solution but Not to Immobilized Von Willebrand Factor Thereby Inhibiting 3-Dimensional but Not 2-Dimensional Thrombus Formation

Domain Specificity of Anti-Prothrombin Antibodies That Express Lupus Anticoagulant Activity

A Novel Plasminogen Activator Anti-Fibrin-uPA Increases the Sensitivity of the Plasmin Generation Assay to Therapeutic Target PAI-1

Flow Cytometric Analysis of Platelet Function in Patients on Antiplatelet Therapy and Suspected Thrombocytopathy

Characterization of a Nanobody That Binds Von Willebrand Factor and Prevents Von Willebrand Factor Cleavage By Plasmin

No Association Between Platelet Function and Hemophilia B Phenotype

Active von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome

Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts

β 2 -glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome

Platelet adhesion to collagen in healthy volunteers is influenced by variation of both α 2 β 1 density and von Willebrand factor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only